董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carol G. Gallagher | 女 | Independent Director and Lead Independent Director | 62 | 17.72万美元 | 25.15 | 2026-10-09 |
| Travis Coy | 男 | Independent Director | 46 | 4.60万美元 | 1.99 | 2026-10-09 |
| Peter Hirth | 男 | Independent Director | 75 | 6.00万美元 | 4.57 | 2026-10-09 |
| Julie Gilmore | 女 | Independent Director | 55 | 未披露 | 未持股 | 2026-10-09 |
| M. Johnston Erwin, Jr. | 男 | Chairman of the Board and Chief Executive Officer and Director | 65 | 139.92万美元 | 65.63 | 2026-10-09 |
| M. Johnston Erwin, Jr. | 男 | Chairman of the Board and Chief Executive Officer and Director | 65 | 未披露 | 未持股 | 2026-10-09 |
| Joel S. Marcus | 男 | Independent Director | 79 | 未披露 | 4.19 | 2026-10-09 |
| Michael Ross | 男 | Independent Director | 77 | 未披露 | 未持股 | 2026-10-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brandon Hants | 男 | Chief Financial Officer | 50 | 未披露 | 未持股 | 2026-10-09 |
| Laura Berner | 女 | Chief Operating Officer | 52 | 77.05万美元 | 19.34 | 2026-10-09 |
| Ariella Kelman | 女 | Chief Medical Officer | 52 | 未披露 | 未持股 | 2026-10-09 |
| Ali Zarrin | 男 | Chief Scientific Officer | 62 | 93.61万美元 | 10.23 | 2026-10-09 |
| M. Johnston Erwin, Jr. | 男 | Chairman of the Board and Chief Executive Officer and Director | 65 | 139.92万美元 | 65.63 | 2026-10-09 |
董事简历
中英对照 | 中文 | 英文- Carol G. Gallagher
-
Carol G. Gallagher，她担任我们的董事会成员（2011年10月以来）。她一直担任New Enterprise Associates公司（一个风险投资公司）的合伙人（2014年10月以来）。她曾一直担任Atara Biotherapeutics公司（公共生物制药公司）的董事（2013年2月以来），并于2014年10月成为首席董事。她也曾担任Atterocor公司的董事（2012年10月以来）、eFFECTOR Therapeutics公司的董事会主席（从2012年10月到2014年）、Aragon Pharmaceuticals公司的董事（从2012年2月到2013年7月）。她曾担任Frazier Healthcare公司（风险投资公司）的风险合伙人（从2013年11月到2014年7月）。她曾担任Calistoga Pharmaceuticals公司（一家生物制药公司）的总裁兼首席执行官（从2008年9月到2011年4月该公司被Gilead Sciences公司收购）。从2007年到2008年，她曾担任Metastatix公司（一个生物制药公司）的总裁兼首席执行官。她曾就读于范德堡大学（Vanderbilt University），并持有肯塔基大学（the University of Kentucky）的药学学士学位和博士学位。
Carol G. Gallagher has served as a member of Trex Bio, Inc.'s board of directors since July 2019 and as Trex Bio, Inc.'s lead independent director since October 2026. From January 2025 through September 2026, Dr. Gallagher served as the chair of Trex Bio, Inc.'s board of directors, and from September 2020 through January 2025, Dr. Gallagher served as executive chair of Trex Bio, Inc.'s board of directors. From October 2014 to December 2023, Dr. Gallagher served as a partner, venture partner and venture advisor at New Enterprise Associates, a venture capital firm. Prior to joining New Enterprise Associates, Dr. Gallagher served as a venture partner with Frazier Healthcare, a venture capital firm, from October 2013 to September 2014. Dr. Gallagher served as the president and chief executive officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from 2008 to 2011, when the company was acquired by Gilead Sciences, Inc. From 2007 to 2008, Dr. Gallagher was the president and chief executive officer of Metastatix, Inc., a biopharmaceutical company. Prior to that time starting in 1989, she served in various roles at pharmaceutical companies, including at Eli Lilly and Company, Amgen, Inc., and Pfizer. Dr. Gallagher serves on the board of directors of Atara Biotherapeutics, Inc. and PMV Pharmaceuticals, Inc. Dr. Gallagher attended Vanderbilt University and holds a B.S. and Doctor of Pharmacy degrees from the University of Kentucky. - Carol G. Gallagher，她担任我们的董事会成员（2011年10月以来）。她一直担任New Enterprise Associates公司（一个风险投资公司）的合伙人（2014年10月以来）。她曾一直担任Atara Biotherapeutics公司（公共生物制药公司）的董事（2013年2月以来），并于2014年10月成为首席董事。她也曾担任Atterocor公司的董事（2012年10月以来）、eFFECTOR Therapeutics公司的董事会主席（从2012年10月到2014年）、Aragon Pharmaceuticals公司的董事（从2012年2月到2013年7月）。她曾担任Frazier Healthcare公司（风险投资公司）的风险合伙人（从2013年11月到2014年7月）。她曾担任Calistoga Pharmaceuticals公司（一家生物制药公司）的总裁兼首席执行官（从2008年9月到2011年4月该公司被Gilead Sciences公司收购）。从2007年到2008年，她曾担任Metastatix公司（一个生物制药公司）的总裁兼首席执行官。她曾就读于范德堡大学（Vanderbilt University），并持有肯塔基大学（the University of Kentucky）的药学学士学位和博士学位。
- Carol G. Gallagher has served as a member of Trex Bio, Inc.'s board of directors since July 2019 and as Trex Bio, Inc.'s lead independent director since October 2026. From January 2025 through September 2026, Dr. Gallagher served as the chair of Trex Bio, Inc.'s board of directors, and from September 2020 through January 2025, Dr. Gallagher served as executive chair of Trex Bio, Inc.'s board of directors. From October 2014 to December 2023, Dr. Gallagher served as a partner, venture partner and venture advisor at New Enterprise Associates, a venture capital firm. Prior to joining New Enterprise Associates, Dr. Gallagher served as a venture partner with Frazier Healthcare, a venture capital firm, from October 2013 to September 2014. Dr. Gallagher served as the president and chief executive officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from 2008 to 2011, when the company was acquired by Gilead Sciences, Inc. From 2007 to 2008, Dr. Gallagher was the president and chief executive officer of Metastatix, Inc., a biopharmaceutical company. Prior to that time starting in 1989, she served in various roles at pharmaceutical companies, including at Eli Lilly and Company, Amgen, Inc., and Pfizer. Dr. Gallagher serves on the board of directors of Atara Biotherapeutics, Inc. and PMV Pharmaceuticals, Inc. Dr. Gallagher attended Vanderbilt University and holds a B.S. and Doctor of Pharmacy degrees from the University of Kentucky.
- Travis Coy
-
Travis Coy自2021年11月起担任Trex Bio，Inc.董事会成员。Coy先生自2025年1月起担任Immunocore控股有限公司的首席财务官和企业发展主管。此前，Coy先生于2019年10月至2024年12月在礼来公司担任副总裁、交易和并购、企业业务发展主管。在担任这一职务之前，Coy先生从2003年开始在礼来公司拥有各种财务和业务发展经验，包括担任副总裁职务，负责交易——肿瘤学和诊断；副总裁，负责交易——心脏代谢疾病、药物递送和设备；肿瘤业务部门财务总监；投资者关系总监；公司财务和投资银行业务总监；以及其他财务总监职务。在过渡到金融和业务发展之前，他是礼来研究实验室的化学家，也是Milliken & Company的生产经理。Coy先生还自2019年9月起担任Immunocore控股有限公司的董事会成员。Coy先生拥有罗斯胡尔曼理工学院的化学学士学位和密歇根大学罗斯商学院的MBA学位。
Travis Coy has served as a member of Trex Bio, Inc.'s board of directors since November 2021. Mr. Coy has served as the chief financial officer and head of corporate development at Immunocore Holdings plc since January 2025. Previously, Mr. Coy served as vice president, head of transactions and M&A, corporate business development at Eli Lilly and Company from October 2019 to December 2024. Prior to this role, Mr. Coy had a variety of finance and business development experiences at Lilly beginning in 2003, including positions as vice president, transactions – oncology and diagnostics; vice president, transactions – cardiometabolic diseases, drug delivery and devices; finance director of the oncology business unit; director of investor relations; director of corporate finance and investment banking; and oter financial controllership roles. Before transitioning to finance and business development, he was a chemist in Lilly's research laboratories and a production manager for Milliken & Company. Mr. Coy has also been a member of the board of directors at Immunocore Holdings plc since September 2019. Mr. Coy holds a BS in Chemistry from Rose Hulman Institute of Technology and an MBA from the Ross School of Business at the University of Michigan. - Travis Coy自2021年11月起担任Trex Bio，Inc.董事会成员。Coy先生自2025年1月起担任Immunocore控股有限公司的首席财务官和企业发展主管。此前，Coy先生于2019年10月至2024年12月在礼来公司担任副总裁、交易和并购、企业业务发展主管。在担任这一职务之前，Coy先生从2003年开始在礼来公司拥有各种财务和业务发展经验，包括担任副总裁职务，负责交易——肿瘤学和诊断；副总裁，负责交易——心脏代谢疾病、药物递送和设备；肿瘤业务部门财务总监；投资者关系总监；公司财务和投资银行业务总监；以及其他财务总监职务。在过渡到金融和业务发展之前，他是礼来研究实验室的化学家，也是Milliken & Company的生产经理。Coy先生还自2019年9月起担任Immunocore控股有限公司的董事会成员。Coy先生拥有罗斯胡尔曼理工学院的化学学士学位和密歇根大学罗斯商学院的MBA学位。
- Travis Coy has served as a member of Trex Bio, Inc.'s board of directors since November 2021. Mr. Coy has served as the chief financial officer and head of corporate development at Immunocore Holdings plc since January 2025. Previously, Mr. Coy served as vice president, head of transactions and M&A, corporate business development at Eli Lilly and Company from October 2019 to December 2024. Prior to this role, Mr. Coy had a variety of finance and business development experiences at Lilly beginning in 2003, including positions as vice president, transactions – oncology and diagnostics; vice president, transactions – cardiometabolic diseases, drug delivery and devices; finance director of the oncology business unit; director of investor relations; director of corporate finance and investment banking; and oter financial controllership roles. Before transitioning to finance and business development, he was a chemist in Lilly's research laboratories and a production manager for Milliken & Company. Mr. Coy has also been a member of the board of directors at Immunocore Holdings plc since September 2019. Mr. Coy holds a BS in Chemistry from Rose Hulman Institute of Technology and an MBA from the Ross School of Business at the University of Michigan.
- Peter Hirth
-
Peter Hirth于2019年7月起担任Trex Bio，Inc.董事会成员。Hirth博士在生物技术和药物发现与开发方面拥有超过30年的经验。在进入生物技术领域之前，Hirth博士曾担任德国勃林格曼海姆公司的研究副总裁。从1991年到2000年，他在Sugen，Inc.担任过多个职位，最终担任总裁，在那里他从一开始就帮助建立公司，并通过肿瘤学的临床试验推进激酶抑制剂。Sugen于1999年被Pharmacia/辉瑞收购。2001年，Hirth博士创立了制药公司PlexXikon，Inc.，并担任首席执行官至2013年4月。PlexXikon于2011年被Daiichi Sankyo收购。Hirth博士目前在Aligos Therapeutics、IO Biotech，Inc.以及多家私营公司的董事会任职。此前曾于2017年1月至2025年4月担任Vaxcyte，公司董事会成员。Hirth博士拥有德国海德堡大学分子遗传学理学硕士和博士学位，并在加州大学圣地亚哥分校完成博士后工作。
Peter Hirth has served as a member of Trex Bio, Inc.'s board of directors since July 2019. Dr. Hirth has over 30 years of experience in biotechnology and pharmaceutical discovery and development. Prior to entering the biotechnology sector, Dr. Hirth served as vice president of Research at Boehringer Mannheim in Germany. From 1991 to 2000, he held several positions at Sugen, Inc., ultimately serving as President, where he helped build the company from inception and advance kinase inhibitors through clinical trials in oncology. Sugen was acquired by Pharmacia/Pfizer in 1999. In 2001, Dr. Hirth co founded Plexxikon, Inc., a pharmaceutical company, and served as its chief executive officer until April 2013. Plexxikon was acquired by Daiichi Sankyo in 2011. Dr. Hirth currently serves on the board of directors of Aligos Therapeutics, IO Biotech, Inc., and several private companies. He previously served on the board of directors of Vaxcyte, Inc. from January 2017 to April 2025. Dr. Hirth holds an MSc and PhD in Molecular Genetics from Heidelberg University, Germany and completed his post doctoral work at the University of California, San Diego. - Peter Hirth于2019年7月起担任Trex Bio，Inc.董事会成员。Hirth博士在生物技术和药物发现与开发方面拥有超过30年的经验。在进入生物技术领域之前，Hirth博士曾担任德国勃林格曼海姆公司的研究副总裁。从1991年到2000年，他在Sugen，Inc.担任过多个职位，最终担任总裁，在那里他从一开始就帮助建立公司，并通过肿瘤学的临床试验推进激酶抑制剂。Sugen于1999年被Pharmacia/辉瑞收购。2001年，Hirth博士创立了制药公司PlexXikon，Inc.，并担任首席执行官至2013年4月。PlexXikon于2011年被Daiichi Sankyo收购。Hirth博士目前在Aligos Therapeutics、IO Biotech，Inc.以及多家私营公司的董事会任职。此前曾于2017年1月至2025年4月担任Vaxcyte，公司董事会成员。Hirth博士拥有德国海德堡大学分子遗传学理学硕士和博士学位，并在加州大学圣地亚哥分校完成博士后工作。
- Peter Hirth has served as a member of Trex Bio, Inc.'s board of directors since July 2019. Dr. Hirth has over 30 years of experience in biotechnology and pharmaceutical discovery and development. Prior to entering the biotechnology sector, Dr. Hirth served as vice president of Research at Boehringer Mannheim in Germany. From 1991 to 2000, he held several positions at Sugen, Inc., ultimately serving as President, where he helped build the company from inception and advance kinase inhibitors through clinical trials in oncology. Sugen was acquired by Pharmacia/Pfizer in 1999. In 2001, Dr. Hirth co founded Plexxikon, Inc., a pharmaceutical company, and served as its chief executive officer until April 2013. Plexxikon was acquired by Daiichi Sankyo in 2011. Dr. Hirth currently serves on the board of directors of Aligos Therapeutics, IO Biotech, Inc., and several private companies. He previously served on the board of directors of Vaxcyte, Inc. from January 2017 to April 2025. Dr. Hirth holds an MSc and PhD in Molecular Genetics from Heidelberg University, Germany and completed his post doctoral work at the University of California, San Diego.
- Julie Gilmore
-
Julie Gilmore自2024年12月起担任Trex Bio，Inc.董事会成员。Gilmore博士曾在礼来公司工作近20年，担任副总裁兼Gateway Labs by Lilly和Catalyze360 Portfolio Management全球负责人。她还担任IgGenix，Inc.和Mozart Therapeutics的董事会成员。她在普渡大学获得生物物理学博士学位，并以研究膜生物物理学的博士后身份进入印第安纳大学医学院。
Julie Gilmore has served as a member of Trex Bio, Inc.'s board of directors since December 2024. Dr. Gilmore has spent nearly 20 years at Eli Lilly and Company, serving as vice president and global head of Gateway Labs by Lilly and Catalyze360 Portfolio Management. She also serves on the board of IgGenix, Inc. and Mozart Therapeutics. She received a PhD in biophysics from Purdue University and attended Indiana University School of Medicine as a post doctoral fellow studying membrane biophysics. - Julie Gilmore自2024年12月起担任Trex Bio，Inc.董事会成员。Gilmore博士曾在礼来公司工作近20年，担任副总裁兼Gateway Labs by Lilly和Catalyze360 Portfolio Management全球负责人。她还担任IgGenix，Inc.和Mozart Therapeutics的董事会成员。她在普渡大学获得生物物理学博士学位，并以研究膜生物物理学的博士后身份进入印第安纳大学医学院。
- Julie Gilmore has served as a member of Trex Bio, Inc.'s board of directors since December 2024. Dr. Gilmore has spent nearly 20 years at Eli Lilly and Company, serving as vice president and global head of Gateway Labs by Lilly and Catalyze360 Portfolio Management. She also serves on the board of IgGenix, Inc. and Mozart Therapeutics. She received a PhD in biophysics from Purdue University and attended Indiana University School of Medicine as a post doctoral fellow studying membrane biophysics.
- M. Johnston Erwin, Jr.
-
M. Johnston Erwin，Jr.自2021年5月起担任Trex Bio，Inc.首席执行官和Trex Bio，Inc.董事会成员，并自2026年10月起担任Trex Bio，Inc.董事会主席。他在监管、临床和企业发展领域的领导角色方面拥有超过40年的经验。在加入TRExBio之前，Erwin先生在礼来公司工作了36年。在2014年至2021年期间，他领导了礼来内部风险资本投资团队Lilly New Ventures，在多家私营生物制药公司的董事会任职。在他任职期间，礼来新创业的投资资本增长超过5倍，连续7年为现金正数。在他退休时，礼来公司有超过45笔直接投资。在其职业生涯的早期，欧文先生领导了为Evista和Forteo品牌提交全球监管文件的临床团队。在他的领导下，这两个品牌都在80多个国家获得批准，每个品牌的全球销售额都达到了10亿美元以上。欧文先生获得了俄勒冈州立大学的学士学位。
M. Johnston Erwin, Jr. has served as Trex Bio, Inc.'s Chief Executive Officer and a member of Trex Bio, Inc.'s board of directors since May 2021 and has served as chair of Trex Bio, Inc.'s board of directors since October 2026. He has over 40 years of experience in leadership roles across regulatory, clinical and corporate development. Prior to joining TRexBio, Mr. Erwin spent 36 years at Eli Lilly and Company. Between 2014 and 2021, he led Lilly New Ventures, Lilly's internal venture capital investment team, serving on the board of a number of private biopharma companies. During his tenure, Lilly New Venture's invested capital grew more than five times and was cash on cash positive for seven consecutive years. At his retirement, Lilly had more than 45 direct investments. Earlier in his career, Mr. Erwin led the clinical team which made global regulatory submissions for the brands of Evista and Forteo. Under his leadership, both brands were approved in more than 80 countries and each reached greater than $1 billion in worldwide sales. Mr. Erwin received his BAS from Oregon State University. - M. Johnston Erwin，Jr.自2021年5月起担任Trex Bio，Inc.首席执行官和Trex Bio，Inc.董事会成员，并自2026年10月起担任Trex Bio，Inc.董事会主席。他在监管、临床和企业发展领域的领导角色方面拥有超过40年的经验。在加入TRExBio之前，Erwin先生在礼来公司工作了36年。在2014年至2021年期间，他领导了礼来内部风险资本投资团队Lilly New Ventures，在多家私营生物制药公司的董事会任职。在他任职期间，礼来新创业的投资资本增长超过5倍，连续7年为现金正数。在他退休时，礼来公司有超过45笔直接投资。在其职业生涯的早期，欧文先生领导了为Evista和Forteo品牌提交全球监管文件的临床团队。在他的领导下，这两个品牌都在80多个国家获得批准，每个品牌的全球销售额都达到了10亿美元以上。欧文先生获得了俄勒冈州立大学的学士学位。
- M. Johnston Erwin, Jr. has served as Trex Bio, Inc.'s Chief Executive Officer and a member of Trex Bio, Inc.'s board of directors since May 2021 and has served as chair of Trex Bio, Inc.'s board of directors since October 2026. He has over 40 years of experience in leadership roles across regulatory, clinical and corporate development. Prior to joining TRexBio, Mr. Erwin spent 36 years at Eli Lilly and Company. Between 2014 and 2021, he led Lilly New Ventures, Lilly's internal venture capital investment team, serving on the board of a number of private biopharma companies. During his tenure, Lilly New Venture's invested capital grew more than five times and was cash on cash positive for seven consecutive years. At his retirement, Lilly had more than 45 direct investments. Earlier in his career, Mr. Erwin led the clinical team which made global regulatory submissions for the brands of Evista and Forteo. Under his leadership, both brands were approved in more than 80 countries and each reached greater than $1 billion in worldwide sales. Mr. Erwin received his BAS from Oregon State University.
- M. Johnston Erwin, Jr.
-
暂无中文简介
M. Johnston Erwin, Jr. has served as Trex Bio, Inc.'s Chief Executive Officer and a member of Trex Bio, Inc.'s board of directors since May 2021 and has served as chair of Trex Bio, Inc.'s board of directors since October 2026. He has over 40 years of experience in leadership roles across regulatory, clinical and corporate development. Prior to joining TRexBio, Mr. Erwin spent 36 years at Eli Lilly and Company. Between 2014 and 2021, he led Lilly New Ventures, Lilly's internal venture capital investment team, serving on the board of a number of private biopharma companies. During his tenure, Lilly New Venture's invested capital grew more than five times and was cash on cash positive for seven consecutive years. At his retirement, Lilly had more than 45 direct investments. Earlier in his career, Mr. Erwin led the clinical team which made global regulatory submissions for the brands of Evista and Forteo. Under his leadership, both brands were approved in more than 80 countries and each reached greater than $1 billion in worldwide sales. Mr. Erwin received his BAS from Oregon State University. -
暂无中文简介
- M. Johnston Erwin, Jr. has served as Trex Bio, Inc.'s Chief Executive Officer and a member of Trex Bio, Inc.'s board of directors since May 2021 and has served as chair of Trex Bio, Inc.'s board of directors since October 2026. He has over 40 years of experience in leadership roles across regulatory, clinical and corporate development. Prior to joining TRexBio, Mr. Erwin spent 36 years at Eli Lilly and Company. Between 2014 and 2021, he led Lilly New Ventures, Lilly's internal venture capital investment team, serving on the board of a number of private biopharma companies. During his tenure, Lilly New Venture's invested capital grew more than five times and was cash on cash positive for seven consecutive years. At his retirement, Lilly had more than 45 direct investments. Earlier in his career, Mr. Erwin led the clinical team which made global regulatory submissions for the brands of Evista and Forteo. Under his leadership, both brands were approved in more than 80 countries and each reached greater than $1 billion in worldwide sales. Mr. Erwin received his BAS from Oregon State University.
- Joel S. Marcus
-
Joel S. Marcus，自2013年11月，他曾担任本公司董事。他创立了Alexandria Real Estate Equities公司（REIT）。REIT公司是一家上市的不动产投资信托公司，致力于持有、运营和发展海外高质量和可持续发展的房地产业务以及生命科学行业。自1994年创立该公司以来，他担任其董事，自1997年3月担任首席执行官，并于2007年5月担任该公司董事长。他还联合创始并负责Alexandria Venture Investments部门事务，该部门是REIT公司旗下的战略风险投资部门。在创立Alexandria部门前，他曾在生物制药行业中致力于公司财务、资产市场、风险投资和企业并购方面的事务，并收获了专业技能。他曾是Arthur Young公司的一名执业注册会计师和税务经理，致力于REITs公司的财务和税务方面的事务。他曾在Accelerator公司担任董事，并曾是该公司的原建筑师和联合创始人之一。他还曾在美国癫痫研究所（CURE，Citizens United for Research in Epilepsy）、美国国立卫生研究院基金会（Foundation for the National Institutes of Health （FNIH））、 癌症研究朋友会（Friends of Cancer Research）、Hamner健康科学研究院（The Hamner Institutes for Health Sciences）、 Intra-Cellular Therapies公司、多发性骨髓瘤研究基金会（Multiple Myeloma Research Foundation）、纽约合作伙伴（the Partnership for New York City） 和 Rexford Industrial Realty公司担任董事。他在洛杉矶的加利福尼亚大学（University of California）获得学士学位和法律博士学位。
Joel S. Marcus has served on Trex Bio, Inc.'s board of directors since November 2024. Mr. Marcus is the Executive Chairman and Founder of Alexandria, a real estate investment trust ("REIT") that pioneered life science real estate and transformed it from a specialty niche to a mainstream asset class. Since co founding the company in 1994, Mr. Marcus has led its remarkable growth into a leading REIT focused on the life science industry. Prior to April 2018, Mr. Marcus served as the company's Chairman, Chief Executive Officer, and President. Mr. Marcus founded Alexandria Venture Investments, the company's strategic venture capital platform, in 1996. Alexandria Venture Investments actively invests in disruptive life science companies that are advancing transformative new modalities, platforms, and innovative medicines to meaningfully improve human health. Some of its most notable early stage investments include Alnylam Pharmaceuticals, Google, Intra Cellular Therapies, and Moderna. Mr. Marcus also served on the board of directors of Intra Cellular Therapies, Inc. from 2006 until its acquisition by Johnson & Johnson in 2025. Prior to co founding Alexandria, Mr. Marcus had an extensive legal career and was one of the principal architects of the 1984 Kirin Amgen, Inc. joint venture. He was also a practicing certified public accountant and tax manager with Arthur Young & Co. He earned his undergraduate and JD degrees from the University of California, Los Angeles. - Joel S. Marcus，自2013年11月，他曾担任本公司董事。他创立了Alexandria Real Estate Equities公司（REIT）。REIT公司是一家上市的不动产投资信托公司，致力于持有、运营和发展海外高质量和可持续发展的房地产业务以及生命科学行业。自1994年创立该公司以来，他担任其董事，自1997年3月担任首席执行官，并于2007年5月担任该公司董事长。他还联合创始并负责Alexandria Venture Investments部门事务，该部门是REIT公司旗下的战略风险投资部门。在创立Alexandria部门前，他曾在生物制药行业中致力于公司财务、资产市场、风险投资和企业并购方面的事务，并收获了专业技能。他曾是Arthur Young公司的一名执业注册会计师和税务经理，致力于REITs公司的财务和税务方面的事务。他曾在Accelerator公司担任董事，并曾是该公司的原建筑师和联合创始人之一。他还曾在美国癫痫研究所（CURE，Citizens United for Research in Epilepsy）、美国国立卫生研究院基金会（Foundation for the National Institutes of Health （FNIH））、 癌症研究朋友会（Friends of Cancer Research）、Hamner健康科学研究院（The Hamner Institutes for Health Sciences）、 Intra-Cellular Therapies公司、多发性骨髓瘤研究基金会（Multiple Myeloma Research Foundation）、纽约合作伙伴（the Partnership for New York City） 和 Rexford Industrial Realty公司担任董事。他在洛杉矶的加利福尼亚大学（University of California）获得学士学位和法律博士学位。
- Joel S. Marcus has served on Trex Bio, Inc.'s board of directors since November 2024. Mr. Marcus is the Executive Chairman and Founder of Alexandria, a real estate investment trust ("REIT") that pioneered life science real estate and transformed it from a specialty niche to a mainstream asset class. Since co founding the company in 1994, Mr. Marcus has led its remarkable growth into a leading REIT focused on the life science industry. Prior to April 2018, Mr. Marcus served as the company's Chairman, Chief Executive Officer, and President. Mr. Marcus founded Alexandria Venture Investments, the company's strategic venture capital platform, in 1996. Alexandria Venture Investments actively invests in disruptive life science companies that are advancing transformative new modalities, platforms, and innovative medicines to meaningfully improve human health. Some of its most notable early stage investments include Alnylam Pharmaceuticals, Google, Intra Cellular Therapies, and Moderna. Mr. Marcus also served on the board of directors of Intra Cellular Therapies, Inc. from 2006 until its acquisition by Johnson & Johnson in 2025. Prior to co founding Alexandria, Mr. Marcus had an extensive legal career and was one of the principal architects of the 1984 Kirin Amgen, Inc. joint venture. He was also a practicing certified public accountant and tax manager with Arthur Young & Co. He earned his undergraduate and JD degrees from the University of California, Los Angeles.
- Michael Ross
-
Michael Ross，他是哲学博士。他担任我们的董事（2013年5月以来）。他曾一直担任SV Life Sciences公司（风险资本公司）的执行合伙人（自2001年1月以来）。他也曾担任Didyma公司（生物技术管理咨询公司）的执行合伙人（从1999年到2002年）。此前，他曾担任CyThera公司、 Carta Proteomics 公司、MetaXen公司和Arris Pharmaceutical Corporation的首席执行官。职业生涯早期，他任职于Genentech公司，担任多种职务，包括开发副总裁和药用化学、生物分子副总裁。他曾任职于Arris Pharmaceutical Corporation 和Archemix公司的董事会成员，以及达特茅斯学院塞耶工程学院（ the Thayer School of Engineering at Dartmouth College）的董事会成员。他持有Dartmouth College的学士学位，以及 the California Institute of Technology的哲学博士学位。他也完成了哈佛大学（Harvard University）的分子生物学博士后培训。
Michael Ross has served as a member of Trex Bio, Inc.'s board of directors since January 2020. Dr. Ross has been a senior partner at SV Health Investors since 2001. Prior to this, Dr. Ross served as the founding chief executive officer at MetaXen and Arris Pharmaceutical. In October 1978, Dr. Ross was the tenth employee at Genentech, where he worked for 13 years. He served as Genentech team leader for the Humulin Roferon, Protropin programs and was vice president of development during the development of Activase, Nutropin and Pulmozyme. He then started Genentech's antibody engineering, protein engineering and small molecule discovery effort as vice president of medicinal and biomolecular chemistry. Dr. Ross was the founding chief executive officer of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Viacyte). Dr. Ross received his PhD in Chemistry from the California Institute of Technology and went on to do his post doctoral work at Harvard. - Michael Ross，他是哲学博士。他担任我们的董事（2013年5月以来）。他曾一直担任SV Life Sciences公司（风险资本公司）的执行合伙人（自2001年1月以来）。他也曾担任Didyma公司（生物技术管理咨询公司）的执行合伙人（从1999年到2002年）。此前，他曾担任CyThera公司、 Carta Proteomics 公司、MetaXen公司和Arris Pharmaceutical Corporation的首席执行官。职业生涯早期，他任职于Genentech公司，担任多种职务，包括开发副总裁和药用化学、生物分子副总裁。他曾任职于Arris Pharmaceutical Corporation 和Archemix公司的董事会成员，以及达特茅斯学院塞耶工程学院（ the Thayer School of Engineering at Dartmouth College）的董事会成员。他持有Dartmouth College的学士学位，以及 the California Institute of Technology的哲学博士学位。他也完成了哈佛大学（Harvard University）的分子生物学博士后培训。
- Michael Ross has served as a member of Trex Bio, Inc.'s board of directors since January 2020. Dr. Ross has been a senior partner at SV Health Investors since 2001. Prior to this, Dr. Ross served as the founding chief executive officer at MetaXen and Arris Pharmaceutical. In October 1978, Dr. Ross was the tenth employee at Genentech, where he worked for 13 years. He served as Genentech team leader for the Humulin Roferon, Protropin programs and was vice president of development during the development of Activase, Nutropin and Pulmozyme. He then started Genentech's antibody engineering, protein engineering and small molecule discovery effort as vice president of medicinal and biomolecular chemistry. Dr. Ross was the founding chief executive officer of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Viacyte). Dr. Ross received his PhD in Chemistry from the California Institute of Technology and went on to do his post doctoral work at Harvard.
高管简历
中英对照 | 中文 | 英文- Brandon Hants
Brandon Hants自2025年2月起担任Trex Bio，Inc.的首席财务官。在加入Trex Bio，Inc.之前，Hants先生曾在Applied Molecular运输公司担任首席财务官，该公司是一家临床阶段的生物治疗公司，开发了一系列新型口服生物候选产品。在此之前，他曾在免疫诊断公司Singulex, Inc.担任多个职务，包括首席财务官以及财务和运营副总裁。在加入Singulex之前，汉茨先生在诺华疫苗与诊断公司和基因泰克公司担任越来越重要的职务。汉茨先生拥有加州大学圣巴巴拉分校的细胞和发育生物学学士学位，以及旧金山大学的MBA学位。
Brandon Hants has served as Trex Bio, Inc.'s Chief Financial Officer since February 2025. Prior to joining Trex Bio, Inc., Mr. Hants served as chief financial officer at Applied Molecular Transport, a clinical stage biotherapeutics company that developed a pipeline of novel oral biologic product candidates. Prior to that, he held various roles at Singulex, Inc., an immunodiagnostics company, including chief financial officer and vice president of finance and operations. Prior to Singulex, Mr. Hants held roles of increasing responsibility at Novartis Vaccines & Diagnostics and Genentech. Mr. Hants holds a BS in Cell and Developmental Biology from the University of California, Santa Barbara, and an MBA from the University of San Francisco.- Brandon Hants自2025年2月起担任Trex Bio，Inc.的首席财务官。在加入Trex Bio，Inc.之前，Hants先生曾在Applied Molecular运输公司担任首席财务官，该公司是一家临床阶段的生物治疗公司，开发了一系列新型口服生物候选产品。在此之前，他曾在免疫诊断公司Singulex, Inc.担任多个职务，包括首席财务官以及财务和运营副总裁。在加入Singulex之前，汉茨先生在诺华疫苗与诊断公司和基因泰克公司担任越来越重要的职务。汉茨先生拥有加州大学圣巴巴拉分校的细胞和发育生物学学士学位，以及旧金山大学的MBA学位。
- Brandon Hants has served as Trex Bio, Inc.'s Chief Financial Officer since February 2025. Prior to joining Trex Bio, Inc., Mr. Hants served as chief financial officer at Applied Molecular Transport, a clinical stage biotherapeutics company that developed a pipeline of novel oral biologic product candidates. Prior to that, he held various roles at Singulex, Inc., an immunodiagnostics company, including chief financial officer and vice president of finance and operations. Prior to Singulex, Mr. Hants held roles of increasing responsibility at Novartis Vaccines & Diagnostics and Genentech. Mr. Hants holds a BS in Cell and Developmental Biology from the University of California, Santa Barbara, and an MBA from the University of San Francisco.
- Laura Berner
Laura Berner自2022年5月起担任Trex Bio，Inc.的首席运营官。她于2020年8月加入TRXBio，担任首席商务官，负责推动TRXBio，Inc.的战略、业务和企业发展事务。Berner女士在公共和私营生物制药公司的业务战略、企业发展和法律事务方面拥有25年的经验。自加入TRXBio以来，她负责监督Trex Bio，Inc.的股权融资和Trex Bio，Inc.制药合作的执行。在加入TRExBio之前，她是被Sumitovant Biopharma Ltd.收购的Myovant Sciences的业务发展和投资者关系主管。在她职业生涯的早期，她领导了罗氏制药部门和基因泰克制药部门的重要合作和并购交易。她的职业生涯始于私人执业的企业和生命科学交易律师。Berner女士在布林莫尔学院获得生物学学士学位，在斯坦福大学法学院获得京东学位，在伊利诺伊大学厄巴纳香槟分校（英语：University of Illinois Urbana Champaign，Gies）获得MBA学位。她目前在Bolt Biotherapeutics董事会任职。
Laura Berner has served as Trex Bio, Inc.'s Chief Operating Officer since May 2022. She joined TRexBio as Chief Business Officer in August 2020, and drives Trex Bio, Inc.'s strategic, business and corporate development matters. Ms. Berner has 25 years of experience across business strategy, corporate development and legal affairs at public and private biopharmaceutical companies. Since joining TRexBio, she has overseen Trex Bio, Inc.'s equity financings and the execution of Trex Bio, Inc.'s pharma collaborations. Prior to TRexBio she was Head of Business Development and Investor Relations at Myovant Sciences, which was acquired by Sumitovant Biopharma Ltd. Earlier in her career she led significant partnering and merger and acquisitions transactions for the pharmaceutical divisions at Roche and Genentech. She started her career as a corporate and life sciences transactions attorney in private practice. Ms. Berner obtained her BA in biology from Bryn Mawr College, her JD from Stanford Law School and her MBA from the University of Illinois Urbana Champaign (Gies). She currently serves on the board of directors of Bolt Biotherapeutics.- Laura Berner自2022年5月起担任Trex Bio，Inc.的首席运营官。她于2020年8月加入TRXBio，担任首席商务官，负责推动TRXBio，Inc.的战略、业务和企业发展事务。Berner女士在公共和私营生物制药公司的业务战略、企业发展和法律事务方面拥有25年的经验。自加入TRXBio以来，她负责监督Trex Bio，Inc.的股权融资和Trex Bio，Inc.制药合作的执行。在加入TRExBio之前，她是被Sumitovant Biopharma Ltd.收购的Myovant Sciences的业务发展和投资者关系主管。在她职业生涯的早期，她领导了罗氏制药部门和基因泰克制药部门的重要合作和并购交易。她的职业生涯始于私人执业的企业和生命科学交易律师。Berner女士在布林莫尔学院获得生物学学士学位，在斯坦福大学法学院获得京东学位，在伊利诺伊大学厄巴纳香槟分校（英语：University of Illinois Urbana Champaign，Gies）获得MBA学位。她目前在Bolt Biotherapeutics董事会任职。
- Laura Berner has served as Trex Bio, Inc.'s Chief Operating Officer since May 2022. She joined TRexBio as Chief Business Officer in August 2020, and drives Trex Bio, Inc.'s strategic, business and corporate development matters. Ms. Berner has 25 years of experience across business strategy, corporate development and legal affairs at public and private biopharmaceutical companies. Since joining TRexBio, she has overseen Trex Bio, Inc.'s equity financings and the execution of Trex Bio, Inc.'s pharma collaborations. Prior to TRexBio she was Head of Business Development and Investor Relations at Myovant Sciences, which was acquired by Sumitovant Biopharma Ltd. Earlier in her career she led significant partnering and merger and acquisitions transactions for the pharmaceutical divisions at Roche and Genentech. She started her career as a corporate and life sciences transactions attorney in private practice. Ms. Berner obtained her BA in biology from Bryn Mawr College, her JD from Stanford Law School and her MBA from the University of Illinois Urbana Champaign (Gies). She currently serves on the board of directors of Bolt Biotherapeutics.
- Ariella Kelman
Ariella Kelman自2025年3月起担任Trex Bio，Inc.的首席医疗官。此前，Kelman博士在Biora Therapeutics担任首席医疗官，在此之前，她在Human Immunology Biosciences领导临床开发。在此之前，Kelman博士在基因泰克工作了15年，在那里她领导了针对炎症和自身免疫性疾病的几种新药的临床开发项目，随后担任罗氏生物伦理学的全球负责人。Kelman博士在斯坦福大学医院免疫学和风湿病科担任了10年的主治医师。Kelman博士拥有加州大学洛杉矶分校的学士学位和特拉维夫大学的医学博士学位。她在洛杉矶的凯撒医院和圣克拉拉完成了内科住院医师实习，并在斯坦福大学医院完成了风湿病学和临床研究方面的研究金。
Ariella Kelman has served as Trex Bio, Inc.'s Chief Medical Officer since March 2025. Previously, Dr. Kelman served as chief medical officer at Biora Therapeutics, and before that, she led clinical development at Human Immunology Biosciences. Prior to that, Dr. Kelman spent 15 years at Genentech, where she led clinical development programs for several new medicines for inflammatory and autoimmune diseases and subsequently served as global head of bioethics for Roche. Dr. Kelman was an attending physician for 10 years in the Division of Immunology and Rheumatology at Stanford University Hospital. Dr. Kelman holds a BS from UCLA, and an MD from Tel Aviv University. She completed her residency in internal medicine at Kaiser Hospitals in Los Angeles and Santa Clara and completed fellowships in rheumatology and clinical research at Stanford University Hospital.- Ariella Kelman自2025年3月起担任Trex Bio，Inc.的首席医疗官。此前，Kelman博士在Biora Therapeutics担任首席医疗官，在此之前，她在Human Immunology Biosciences领导临床开发。在此之前，Kelman博士在基因泰克工作了15年，在那里她领导了针对炎症和自身免疫性疾病的几种新药的临床开发项目，随后担任罗氏生物伦理学的全球负责人。Kelman博士在斯坦福大学医院免疫学和风湿病科担任了10年的主治医师。Kelman博士拥有加州大学洛杉矶分校的学士学位和特拉维夫大学的医学博士学位。她在洛杉矶的凯撒医院和圣克拉拉完成了内科住院医师实习，并在斯坦福大学医院完成了风湿病学和临床研究方面的研究金。
- Ariella Kelman has served as Trex Bio, Inc.'s Chief Medical Officer since March 2025. Previously, Dr. Kelman served as chief medical officer at Biora Therapeutics, and before that, she led clinical development at Human Immunology Biosciences. Prior to that, Dr. Kelman spent 15 years at Genentech, where she led clinical development programs for several new medicines for inflammatory and autoimmune diseases and subsequently served as global head of bioethics for Roche. Dr. Kelman was an attending physician for 10 years in the Division of Immunology and Rheumatology at Stanford University Hospital. Dr. Kelman holds a BS from UCLA, and an MD from Tel Aviv University. She completed her residency in internal medicine at Kaiser Hospitals in Los Angeles and Santa Clara and completed fellowships in rheumatology and clinical research at Stanford University Hospital.
- Ali Zarrin
Ali Zarrin自2025年8月起担任Trex Bio，Inc.的首席科学官。他于2019年8月加入TRExBio，曾领导开发Trex Bio，Inc.专有的Deep Biology平台以及Trex Bio，Inc.候选产品的转化活动。Zarrin博士是一位成就卓著的免疫学家，在免疫生物学、药物发现和转化免疫学领域拥有超过25年的经验。在加入TREXBio之前，Zarrin博士在基因泰克的早期研发领域担任领导职务，专注于自身免疫性疾病和炎症性疾病。他是多项专利的发明人，在主要期刊上撰写了近50篇科学出版物。Zarrin博士在明尼苏达大学获得学士学位，在多伦多大学获得免疫学博士学位，并在霍华德休斯医学研究所和哈佛医学院的开创性遗传学家和分子免疫学家Fred Alt的实验室进行博士后研究。
Ali Zarrin has served as Trex Bio, Inc.'s Chief Scientific Officer since August 2025. He joined TRexBio in August of 2019 and has led the development of Trex Bio, Inc.'s proprietary Deep Biology platform and the translational activities for Trex Bio, Inc.'s product candidates. Dr. Zarrin is an accomplished immunologist with more than 25 years of experience across immunobiology, drug discovery and translational immunology. Prior to TRexBio, Dr. Zarrin held leadership roles in Early Research and Development at Genentech, with a focus on autoimmune and inflammatory diseases. He is an inventor on multiple patents and has authored close to 50 scientific publications in leading journals. Dr. Zarrin earned his BS from the University of Minnesota, his PhD in Immunology from the University of Toronto, and conducted postdoctoral studies in the laboratory of pioneering geneticist and molecular immunologist Fred Alt at the Howard Hughes Medical Institute and Harvard Medical School.- Ali Zarrin自2025年8月起担任Trex Bio，Inc.的首席科学官。他于2019年8月加入TRExBio，曾领导开发Trex Bio，Inc.专有的Deep Biology平台以及Trex Bio，Inc.候选产品的转化活动。Zarrin博士是一位成就卓著的免疫学家，在免疫生物学、药物发现和转化免疫学领域拥有超过25年的经验。在加入TREXBio之前，Zarrin博士在基因泰克的早期研发领域担任领导职务，专注于自身免疫性疾病和炎症性疾病。他是多项专利的发明人，在主要期刊上撰写了近50篇科学出版物。Zarrin博士在明尼苏达大学获得学士学位，在多伦多大学获得免疫学博士学位，并在霍华德休斯医学研究所和哈佛医学院的开创性遗传学家和分子免疫学家Fred Alt的实验室进行博士后研究。
- Ali Zarrin has served as Trex Bio, Inc.'s Chief Scientific Officer since August 2025. He joined TRexBio in August of 2019 and has led the development of Trex Bio, Inc.'s proprietary Deep Biology platform and the translational activities for Trex Bio, Inc.'s product candidates. Dr. Zarrin is an accomplished immunologist with more than 25 years of experience across immunobiology, drug discovery and translational immunology. Prior to TRexBio, Dr. Zarrin held leadership roles in Early Research and Development at Genentech, with a focus on autoimmune and inflammatory diseases. He is an inventor on multiple patents and has authored close to 50 scientific publications in leading journals. Dr. Zarrin earned his BS from the University of Minnesota, his PhD in Immunology from the University of Toronto, and conducted postdoctoral studies in the laboratory of pioneering geneticist and molecular immunologist Fred Alt at the Howard Hughes Medical Institute and Harvard Medical School.
- M. Johnston Erwin, Jr.
M. Johnston Erwin，Jr.自2021年5月起担任Trex Bio，Inc.首席执行官和Trex Bio，Inc.董事会成员，并自2026年10月起担任Trex Bio，Inc.董事会主席。他在监管、临床和企业发展领域的领导角色方面拥有超过40年的经验。在加入TRExBio之前，Erwin先生在礼来公司工作了36年。在2014年至2021年期间，他领导了礼来内部风险资本投资团队Lilly New Ventures，在多家私营生物制药公司的董事会任职。在他任职期间，礼来新创业的投资资本增长超过5倍，连续7年为现金正数。在他退休时，礼来公司有超过45笔直接投资。在其职业生涯的早期，欧文先生领导了为Evista和Forteo品牌提交全球监管文件的临床团队。在他的领导下，这两个品牌都在80多个国家获得批准，每个品牌的全球销售额都达到了10亿美元以上。欧文先生获得了俄勒冈州立大学的学士学位。
M. Johnston Erwin, Jr. has served as Trex Bio, Inc.'s Chief Executive Officer and a member of Trex Bio, Inc.'s board of directors since May 2021 and has served as chair of Trex Bio, Inc.'s board of directors since October 2026. He has over 40 years of experience in leadership roles across regulatory, clinical and corporate development. Prior to joining TRexBio, Mr. Erwin spent 36 years at Eli Lilly and Company. Between 2014 and 2021, he led Lilly New Ventures, Lilly's internal venture capital investment team, serving on the board of a number of private biopharma companies. During his tenure, Lilly New Venture's invested capital grew more than five times and was cash on cash positive for seven consecutive years. At his retirement, Lilly had more than 45 direct investments. Earlier in his career, Mr. Erwin led the clinical team which made global regulatory submissions for the brands of Evista and Forteo. Under his leadership, both brands were approved in more than 80 countries and each reached greater than $1 billion in worldwide sales. Mr. Erwin received his BAS from Oregon State University.- M. Johnston Erwin，Jr.自2021年5月起担任Trex Bio，Inc.首席执行官和Trex Bio，Inc.董事会成员，并自2026年10月起担任Trex Bio，Inc.董事会主席。他在监管、临床和企业发展领域的领导角色方面拥有超过40年的经验。在加入TRExBio之前，Erwin先生在礼来公司工作了36年。在2014年至2021年期间，他领导了礼来内部风险资本投资团队Lilly New Ventures，在多家私营生物制药公司的董事会任职。在他任职期间，礼来新创业的投资资本增长超过5倍，连续7年为现金正数。在他退休时，礼来公司有超过45笔直接投资。在其职业生涯的早期，欧文先生领导了为Evista和Forteo品牌提交全球监管文件的临床团队。在他的领导下，这两个品牌都在80多个国家获得批准，每个品牌的全球销售额都达到了10亿美元以上。欧文先生获得了俄勒冈州立大学的学士学位。
- M. Johnston Erwin, Jr. has served as Trex Bio, Inc.'s Chief Executive Officer and a member of Trex Bio, Inc.'s board of directors since May 2021 and has served as chair of Trex Bio, Inc.'s board of directors since October 2026. He has over 40 years of experience in leadership roles across regulatory, clinical and corporate development. Prior to joining TRexBio, Mr. Erwin spent 36 years at Eli Lilly and Company. Between 2014 and 2021, he led Lilly New Ventures, Lilly's internal venture capital investment team, serving on the board of a number of private biopharma companies. During his tenure, Lilly New Venture's invested capital grew more than five times and was cash on cash positive for seven consecutive years. At his retirement, Lilly had more than 45 direct investments. Earlier in his career, Mr. Erwin led the clinical team which made global regulatory submissions for the brands of Evista and Forteo. Under his leadership, both brands were approved in more than 80 countries and each reached greater than $1 billion in worldwide sales. Mr. Erwin received his BAS from Oregon State University.